Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG01/QS-21 With or Without Balstilimab in Resected Pancreatic Cancer (TESLA)
NCT05638698Phase 2Active, not recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Peptides, Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TG01, balstilimab in pancreatic cancer (PC), sponsored by University of Kansas Medical Center. Started Dec 2022; status: active, not recruiting.
02
Drugs
TG01balstilimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05638698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638698.